

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Neurizon Therapeutics Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sergio Duchini
<b>Date of last notice</b>	7 February 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Kelbury Pty Ltd  Mr Duchini is a Director of the above holder which is the registered holder of the securities
<b>Date of change</b>	23 December 2025
<b>No. of securities held prior to change</b>	<u>Indirect</u>  1,315,789 fully paid ordinary shares  <u>Direct</u>  960,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
<b>Class</b>	Fully paid ordinary shares

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	<u>Indirect</u> 416,667 fully paid ordinary shares
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.12 per Share (\$50,000.04)
<b>No. of securities held after change</b>	<u>Indirect</u>  1,732,456 fully paid ordinary shares  <u>Direct</u>  960,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Placement as announced on 18 September 2025 and as approved by shareholders at the Company's Annual General Meeting held on 26 November 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Neurizon Therapeutics Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr. Michael Thurn
<b>Date of last notice</b>	8 November 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Dr Michael Joseph Thurn &amp; Mrs Carmen Leeann Thurn &lt;Thurn Family A/C&gt;</b>  Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities  <b>Dr Michael Thurn &lt;Thurn Family A/C&gt;</b>  Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities
<b>Date of change</b>	23 December 2025

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><u>Indirect – Dr Michael Joseph Thurn &amp; Mrs Carmen Leeann Thurn &lt;Thurn Family A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 2,821,053 fully paid ordinary shares</li> <li>- 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15</li> </ul> <p><u>Indirect – Dr Michael Thurn &lt;Thurn Family A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 1,000,000 Unlisted Options, expiring 19/01/2026 @ \$0.175</li> </ul> <p><u>Direct</u></p> <ul style="list-style-type: none"> <li>- 1,140,000 Performance Rights expiring 30/06/2027</li> <li>- 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20</li> </ul>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	<u>Indirect</u> 166,667 fully paid ordinary shares
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.12 per Share (\$20,000.04)

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<u>Indirect – Dr Michael Joseph Thurn &amp; Mrs Carmen Leeann Thurn &lt;Thurn Family A/C&gt;</u>  <ul style="list-style-type: none"> <li>- 2,987,720 fully paid ordinary shares</li> <li>- 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15</li> </ul> <u>Indirect – Dr Michael Thurn &lt;Thurn Family A/C&gt;</u>  <ul style="list-style-type: none"> <li>- 1,000,000 Unlisted Options, expiring 19/01/2026 @ \$0.175</li> </ul> <u>Direct</u>  <ul style="list-style-type: none"> <li>- 1,140,000 Performance Rights expiring 30/06/2027</li> <li>- 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Placement as announced on 18 September 2025 and as approved by shareholders at the Company's Annual General Meeting held on 26 November 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Neurizon Therapeutics Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Marcus Hughes
<b>Date of last notice</b>	7 February 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Mr Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</b>  Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities  <b>Ms Antoinette Quinlan</b>  Spouse of Marcus Hughes
<b>Date of change</b>	23 December 2025



**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><u>Direct</u></p> <ul style="list-style-type: none"> <li>- 11,944,079 fully paid ordinary shares</li> <li>- 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032</li> </ul> <p><u>Indirect - Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 2,085,895 fully paid ordinary shares</li> </ul> <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> <li>- 423,895 fully paid ordinary shares</li> </ul>
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	<p><u>Direct</u></p> <p>416,667 fully paid ordinary shares</p>
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.12 per Share (\$50,000.04)
<b>No. of securities held after change</b>	<p><u>Direct</u></p> <ul style="list-style-type: none"> <li>- 12,360,746 fully paid ordinary shares</li> <li>- 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032</li> </ul> <p><u>Indirect - Marcus Paul Hughes &amp; Mr Adam Nicholas Hughes &amp; Mrs Joanne Elvira Hughes &lt;Hughes Family Super Fund A/C&gt;</u></p> <ul style="list-style-type: none"> <li>- 2,085,895 fully paid ordinary shares</li> </ul> <p><u>Indirect – Ms Antoinette Quinlan</u></p> <ul style="list-style-type: none"> <li>- 423,895 fully paid ordinary shares</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Placement as announced on 18 September 2025 and as approved by shareholders at the Company's Annual General Meeting held on 26 November 2025.
--	--

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Neurizon Therapeutics Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Kathryn MacFarlane
<b>Date of last notice</b>	7 February 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	23 December 2025
<b>No. of securities held prior to change</b>	263,158 fully paid ordinary shares  600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	83,334 fully paid ordinary shares
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.12 per Share (\$10,000.08)
<b>No. of securities held after change</b>	346,492 fully paid ordinary shares  600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Placement as announced on 18 September 2025 and as approved by shareholders at the Company's Annual General Meeting held on 26 November 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.